Developer docs
API playgroundTry for free, no card

Search company profiles

Zag Bio

Full company profile

uuid003qbus

Namestring
Zag Bio
Legal namestring
Zag Bio, Inc.
Websiteurl
zagbio.com
Company typeenum
Private
Founded yearint
2025
Descriptiontext

Zag Bio is a Cambridge, Massachusetts-based, privately held biotechnology company developing thymus-targeted bifunctional antibody medicines designed to restore immune tolerance in autoimmune diseases. The company's scientific premise is that the thymus is the only site where self-antigens are presented to induce central T cell tolerance, and that disruption of this process underlies autoimmunity. Its platform engineers antibodies with a thymus-targeting variable domain, an engineered Fc region, and a peripherally fused self-antigen, enabling systemic delivery of disease-relevant antigens to thymic antigen-presenting cells. This promotes deletion of autoreactive T cells and generation of antigen-specific, epigenetically stable regulatory T cells (Tregs) that home to affected tissues and exert localized anti-inflammatory effects without broad immunosuppression.

The company's lead program, ZAG-101, targets pancreatic beta-cell antigens for the disease-modifying treatment of Type 1 diabetes, addressing the approximately 1.5 million U.S. and 9.5 million global patients who currently rely on lifelong insulin therapy without correcting the underlying autoimmune pathology. First-in-human clinical studies are targeted for late 2026, with CMC manufacturing established through a January 2026 partnership with ProBioGen. Discovery-stage programs are also underway in autoimmune indications affecting the gastrointestinal tract, skin, and nervous system, leveraging the platform's modular design.

Zag Bio is pre-revenue and funded by an $80 million Series A closed in October 2025, co-led by Polaris Partners and T1D Fund with participation from AbbVie Ventures, Sanofi Ventures, Regeneron Ventures, Lightspeed Ventures, Mission BioCapital and others. The company is led by CEO Jason F. Cole, CMO Jan Hillson (formerly of Provention Bio), COO Alison Conlon, and CSO and co-founder John Kulman (formerly of CRISPR Therapeutics), with scientific co-founder Diane Mathis of Harvard Medical School providing the foundational immunology expertise. Long-term revenue is expected to be generated through pharmaceutical sales of approved biologics distributed via specialty pharmacy networks and direct provider channels.

Short descriptiontext

Zag Bio is a Cambridge, MA-based pre-clinical biotechnology company developing thymus-targeted bifunctional antibody therapies to restore immune tolerance in autoimmune diseases, with lead program ZAG-101 advancing toward first-in-human studies in Type 1 diabetes by late 2026.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
thymus-targeted antibodies, autoimmune disease therapy, bifunctional antibody medicines, central immune tolerance, biologic drug development
Industry1 code
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code2 codes
  • Medical and Diagnostic Laboratories62151
  • Medical Laboratories621511
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Autoimmune Disease Biologics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Pre-revenue development stage biotech company. Revenue would be generated through sales of ZAG-101 and future thymus-targeted therapies for autoimmune diseases once approved. Typical biotech commercialization model with pricing based on therapeutic value and patient access programs.

zagbio.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Zag Bio designs thymus-targeted bifunctional antibody medicines that deliver self-antigens directly to thymic antigen-presenting cells, inducing central T cell tolerance to address the root cause of autoimmunity rather than broadly suppressing the immune system. The lead clinical candidate ZAG-101 is being developed as a disease-modifying therapy for Type 1 diabetes, with the platform enabling additional pipeline programs across gastrointestinal, skin, and nervous system autoimmune indications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Antigen-specific Tregs uniquely suppress pathogenic immune responses at the site of autoantigen expression without broad immunosuppression
+2 more records
Product overview1 text field

Zag Bio is a biotechnology company pioneering thymus-targeted medicines to treat and prevent autoimmune diseases. The company's core offering consists of ZAG-101, a lead disease-modifying therapy for Type 1 diabetes currently advancing toward clinical development (anticipated first-in-human study in late 2026), built upon a proprietary thymus-targeted bifunctional antibody platform. The platform enables the delivery of self-antigens to the thymus to induce central immune tolerance. Discovery programs are underway for autoimmune diseases affecting the gastrointestinal tract, skin, and nervous system.

Product and service1 record
1ZAG-101
CategoryAutoimmune Disease Biologics
Description

A first-in-class, disease-modifying bifunctional antibody therapy for Type 1 diabetes that delivers pancreatic beta cell antigens to the thymus to restore immune tolerance, expand antigen-specific regulatory T cells, and protect beta cells from destruction in newly diagnosed or at-risk patients who still have functional beta cells.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-07
Description

ProBioGen signed a master service agreement with Zag Bio for cell line development, process development, and GMP manufacturing for Zag Bio's lead product ZAG-101, aimed at preventing or delaying Type 1 diabetes. Clinical development is targeted for late 2026.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

AbCellera is a public antibody discovery platform company partnering with pharma to generate therapeutic antibodies, including for autoimmune indications. Comparable as a bifunctional/therapeutic antibody platform company serving immunology markets.

TypeEmerging player
Description

CRISPR Therapeutics developed Casgevy (the first CRISPR-based therapy), where Zag Bio CSO John Kulman previously served on executive leadership. Comparable as a gene-editing/biologics platform developing first-in-class therapies approved through novel mechanisms.

TypeDirect peer
Description

Alpine Immune Sciences developed engineered protein therapies modulating immune pathways for autoimmune disease, recently acquired by Vertex for $4.9B. Listed as a previous employer of Zag Bio's CMO Jan Hillson, indicating overlap in clinical development expertise.

TypeDirect peer
Description

Provention Bio developed and commercialized Tzield (teplizumab), the only FDA-approved disease-modifying therapy for Type 1 diabetes. Zag Bio's CMO Jan Hillson led Tzield's clinical development there, making Provention the most directly relevant T1D therapeutic competitor.

5Abata Therapeutics
TypeDirect peer
Description

Abata Therapeutics develops Treg-based cell therapies for autoimmune diseases, including Type 1 diabetes, with co-founder Diane Mathis (same as Zag Bio) providing foundational tolerance biology. Direct peer in T1D tolerance-induction approach with shared scientific lineage.

TypeDirect peer
Description

Trex Bio is a Treg cell therapy company co-founded by Diane Mathis (also Zag Bio co-founder). Focuses on tissue-specific regulatory T cells for autoimmune disease, sharing scientific foundation and tolerance-induction approach with Zag Bio.

TypeDirect peer
Description

Seismic Therapeutic is an immunology-focused biotech co-founded by Zag Bio co-founder Jo Viney (current CEO). Develops biologics for autoimmune and inflammatory diseases, making it a closely aligned peer in stage, focus, and founding team overlap.

TypeBroad incumbent
Description

Vertex is advancing VX-880, a stem-cell-derived beta cell replacement therapy for T1D that, if successful, would address the disease by replacing destroyed cells rather than modulating immune response. Represents a competing modality in the same T1D indication Zag Bio targets.

TypeEmerging player
Description

SalioGen Therapeutics was a gene-insertion therapy company where Zag Bio CEO Jason Cole previously served as CEO and Chair. While SalioGen operated in a different modality, it represents prior leadership experience at a similar stage autoimmune/genetic-medicine biotech.

10Pandion Therapeutics
TypeDirect peer
Description

Pandion Therapeutics developed engineered Tregs and immune-modulating biologics for autoimmune diseases, founded by Zag Bio co-founders Alan Crane and Jo Viney, and acquired by Merck for $1.85B. Represents a successful prior instantiation of the autoimmune tolerance approach.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Zag Bio

Autoimmune Disease Biologicszagbio.com

Zag Bio is a Cambridge, MA-based pre-clinical biotechnology company developing thymus-targeted bifunctional antibody therapies to restore immune tolerance in autoimmune diseases, with lead program ZAG-101 advancing toward first-in-human studies in Type 1 diabetes by late 2026.

What Zag Bio does

Zag Bio is a Cambridge, Massachusetts-based, privately held biotechnology company developing thymus-targeted bifunctional antibody medicines designed to restore immune tolerance in autoimmune diseases. The company's scientific premise is that the thymus is the only site where self-antigens are presented to induce central T cell tolerance, and that disruption of this process underlies autoimmunity. Its platform engineers antibodies with a thymus-targeting variable domain, an engineered Fc region, and a peripherally fused self-antigen, enabling systemic delivery of disease-relevant antigens to thymic antigen-presenting cells. This promotes deletion of autoreactive T cells and generation of antigen-specific, epigenetically stable regulatory T cells (Tregs) that home to affected tissues and exert localized anti-inflammatory effects without broad immunosuppression.

The company's lead program, ZAG-101, targets pancreatic beta-cell antigens for the disease-modifying treatment of Type 1 diabetes, addressing the approximately 1.5 million U.S. and 9.5 million global patients who currently rely on lifelong insulin therapy without correcting the underlying autoimmune pathology. First-in-human clinical studies are targeted for late 2026, with CMC manufacturing established through a January 2026 partnership with ProBioGen. Discovery-stage programs are also underway in autoimmune indications affecting the gastrointestinal tract, skin, and nervous system, leveraging the platform's modular design.

Zag Bio is pre-revenue and funded by an $80 million Series A closed in October 2025, co-led by Polaris Partners and T1D Fund with participation from AbbVie Ventures, Sanofi Ventures, Regeneron Ventures, Lightspeed Ventures, Mission BioCapital and others. The company is led by CEO Jason F. Cole, CMO Jan Hillson (formerly of Provention Bio), COO Alison Conlon, and CSO and co-founder John Kulman (formerly of CRISPR Therapeutics), with scientific co-founder Diane Mathis of Harvard Medical School providing the foundational immunology expertise. Long-term revenue is expected to be generated through pharmaceutical sales of approved biologics distributed via specialty pharmacy networks and direct provider channels.

Zag Bio firmographics

Firmographics
Name
Zag Bio
Legal name
Zag Bio, Inc.
Website
https://zagbio.com
Company type
Private
Founded year
2025
Operating status
Operating
Headcount range
11–50 employees
Short description
Zag Bio is a Cambridge, MA-based pre-clinical biotechnology company developing thymus-targeted bifunctional antibody therapies to restore immune tolerance in autoimmune diseases, with lead program ZAG-101 advancing toward first-in-human studies in Type 1 diabetes by late 2026.
Ownership category
akta.pro rank

Zag Bio industry classification

Industry
Product category
Autoimmune Disease Biologics
NAICS
Medical and Diagnostic Laboratories (62151), Medical Laboratories (621511)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Thymus-targeted antibodies
  • Autoimmune disease therapy
  • Bifunctional antibody medicines
  • Central immune tolerance
  • Biologic drug development

Where Zag Bio is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Zag Bio business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Product Sales: Pre-revenue development stage biotech company. Revenue would be generated through sales of ZAG-101 and future thymus-targeted therapies for autoimmune diseases once approved. Typical biotech commercialization model with pricing based on therapeutic value and patient access programs.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Zag Bio product offering

Product offering

Core offering

Zag Bio designs thymus-targeted bifunctional antibody medicines that deliver self-antigens directly to thymic antigen-presenting cells, inducing central T cell tolerance to address the root cause of autoimmunity rather than broadly suppressing the immune system. The lead clinical candidate ZAG-101 is being developed as a disease-modifying therapy for Type 1 diabetes, with the platform enabling additional pipeline programs across gastrointestinal, skin, and nervous system autoimmune indications.

Product overview

Zag Bio is a biotechnology company pioneering thymus-targeted medicines to treat and prevent autoimmune diseases. The company's core offering consists of ZAG-101, a lead disease-modifying therapy for Type 1 diabetes currently advancing toward clinical development (anticipated first-in-human study in late 2026), built upon a proprietary thymus-targeted bifunctional antibody platform. The platform enables the delivery of self-antigens to the thymus to induce central immune tolerance. Discovery programs are underway for autoimmune diseases affecting the gastrointestinal tract, skin, and nervous system.

Differentiator

Problem solved

Functional benefit

Products and services

  • ZAG-101 A first-in-class, disease-modifying bifunctional antibody therapy for Type 1 diabetes that delivers pancreatic beta cell antigens to the thymus to restore immune tolerance, expand antigen-specific regulatory T cells, and protect beta cells from destruction in newly diagnosed or at-risk patients who still have functional beta cells.

Quantifiable outcome

  • Antigen-specific Tregs uniquely suppress pathogenic immune responses at the site of autoantigen expression without broad immunosuppression
  • +2 more outcomes

Companies that use Zag Bio

Customer profile

Segments2 records

Ideal customer profiles2 records

Zag Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Zag Bio partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • ProBioGencoreStrategic or Co-development Partner · 7 January 2026ProBioGen signed a master service agreement with Zag Bio for cell line development, process development, and GMP manufacturing for Zag Bio's lead product ZAG-101, aimed at preventing or delaying Type 1 diabetes. Clinical development is targeted for late 2026.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Zag Bio competitors and assessment

Company assessment

Broad incumbents

  • AbCellera Biologics: AbCellera is a public antibody discovery platform company partnering with pharma to generate therapeutic antibodies, including for autoimmune indications. Comparable as a bifunctional/therapeutic antibody platform company serving immunology markets.
  • Vertex Pharmaceuticals: Vertex is advancing VX-880, a stem-cell-derived beta cell replacement therapy for T1D that, if successful, would address the disease by replacing destroyed cells rather than modulating immune response. Represents a competing modality in the same T1D indication Zag Bio targets.

Emerging players

  • CRISPR Therapeutics: CRISPR Therapeutics developed Casgevy (the first CRISPR-based therapy), where Zag Bio CSO John Kulman previously served on executive leadership. Comparable as a gene-editing/biologics platform developing first-in-class therapies approved through novel mechanisms.
  • SalioGen Therapeutics: SalioGen Therapeutics was a gene-insertion therapy company where Zag Bio CEO Jason Cole previously served as CEO and Chair. While SalioGen operated in a different modality, it represents prior leadership experience at a similar stage autoimmune/genetic-medicine biotech.

Direct peers

  • Alpine Immune Sciences: Alpine Immune Sciences developed engineered protein therapies modulating immune pathways for autoimmune disease, recently acquired by Vertex for $4.9B. Listed as a previous employer of Zag Bio's CMO Jan Hillson, indicating overlap in clinical development expertise.
  • Provention Bio (Sanofi): Provention Bio developed and commercialized Tzield (teplizumab), the only FDA-approved disease-modifying therapy for Type 1 diabetes. Zag Bio's CMO Jan Hillson led Tzield's clinical development there, making Provention the most directly relevant T1D therapeutic competitor.
  • Abata Therapeutics: Abata Therapeutics develops Treg-based cell therapies for autoimmune diseases, including Type 1 diabetes, with co-founder Diane Mathis (same as Zag Bio) providing foundational tolerance biology. Direct peer in T1D tolerance-induction approach with shared scientific lineage.
  • Trex Bio: Trex Bio is a Treg cell therapy company co-founded by Diane Mathis (also Zag Bio co-founder). Focuses on tissue-specific regulatory T cells for autoimmune disease, sharing scientific foundation and tolerance-induction approach with Zag Bio.
  • Seismic Therapeutic: Seismic Therapeutic is an immunology-focused biotech co-founded by Zag Bio co-founder Jo Viney (current CEO). Develops biologics for autoimmune and inflammatory diseases, making it a closely aligned peer in stage, focus, and founding team overlap.
  • Pandion Therapeutics: Pandion Therapeutics developed engineered Tregs and immune-modulating biologics for autoimmune diseases, founded by Zag Bio co-founders Alan Crane and Jo Viney, and acquired by Merck for $1.85B. Represents a successful prior instantiation of the autoimmune tolerance approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Zag Bio social profiles

Digital presence

Zag Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Zag Bio leadership team

Management profile

Number of profiles

Profiles7 records

Zag Bio funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Zag Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Zag Bio

What does Zag Bio do?

Zag Bio designs thymus-targeted bifunctional antibody medicines that deliver self-antigens directly to thymic antigen-presenting cells, inducing central T cell tolerance to address the root cause of autoimmunity rather than broadly suppressing the immune system. The lead clinical candidate ZAG-101 is being developed as a disease-modifying therapy for Type 1 diabetes, with the platform enabling additional pipeline programs across gastrointestinal, skin, and nervous system autoimmune indications.

Is Zag Bio a public or private company?

Zag Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Zag Bio founded?

Zag Bio was founded in 2025. It employs 11 to 50 people.

Where is Zag Bio based?

Zag Bio is headquartered in Cambridge, United States, in the North America region.

How does Zag Bio make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Zag Bio's main competitors?

Broad incumbents on record are AbCellera Biologics and Vertex Pharmaceuticals. Emerging players are CRISPR Therapeutics and SalioGen Therapeutics. Direct peers are Alpine Immune Sciences, Provention Bio (Sanofi), Abata Therapeutics, Trex Bio, Seismic Therapeutic and Pandion Therapeutics.

Does Zag Bio have an API?

No public API is recorded for Zag Bio.

What industry is Zag Bio in?

Zag Bio's product category is Autoimmune Disease Biologics. Its primary akta.pro industry code is HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs). Its NAICS code is 62151 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageZag Bio Advances ZAG-101 into Clinical Development for Type 1 DiabetesZag Bio advanced its lead Type 1 diabetes program ZAG-101 into clinical development, launching a Phase 1b/2a trial (LANTERN) to evaluate safety and pharmacology. The trial will measure C-peptide for early efficacy signals and initially enroll adults in Australia and Europe. The company plans to expand to adolescents and earlier disease stages.NatureCould this mysterious disappearing organ hold the key to longevity?A surge of thymus regeneration research has emerged following studies showing that thymus health correlates with mortality risk, prompting multiple biotech companies to pursue therapies aimed at slowing ageing and preventing cancer. Intervene Immune, the company running clinical trials led by Gregory Fahy, and rival firms TECregen and Zag Bio have collectively raised nearly $90 million in funding to develop thymus regeneration treatments. Scientific interest has intensified as recent research found that people with surgically removed thymuses were nearly three times more likely to die and twice as likely to develop cancer within five years.Labiotech.euTreg cell therapy: A promising approach to targeting autoimmunityMultiple biotech companies are advancing regulatory T cell (Treg) therapies for autoimmune diseases, with Sonoma Biotherapeutics reporting positive Phase 1 trial data for its CAR-Treg candidate SBT-77-7101 showing significant reductions in joint swelling in rheumatoid arthritis patients, while Coya Therapeutics secured FDA IND approval for its Treg-enhancing therapy COYA 301 and began Phase 2 studies targeting ALS. London-based Quell Therapeutics halted development of its liver transplant candidate QEL-001 to focus on QEL-005 for rheumatoid arthritis under an $85 million AstraZeneca partnership, and new entrant Zag Bio launched with an $80 million Series A to pursue thymic-based Treg approaches for type 1 diabetes.The Pharma LetterProBioGen and Zag Bio forge strategic CMC partnershipGerman company ProBioGen signed a master service agreement with US biotech Zag Bio, involving cell line development, process development, and GMP manufacturing for Zag Bio's lead product ZAG-101, aimed at preventing or delaying Type 1 diabetes, with clinical development targeted for late 2026. Zag Bio, founded in October last year, has secured $80 million including recent Series A financing.BiotechnewswireProBioGen and Zag Bio™ Forge Strategic CMC Partnership to Advance Fc-Fusion Autoimmune TherapyProBioGen and Zag Bio signed a Master Service Agreement to collaborate on developing Zag Bio's ZAG-101 autoimmune therapy targeting Type 1 diabetes. ProBioGen will provide cell line development, process development, and GMP manufacturing services for the therapy, aiming for clinical development entry in late 2026.VC News DailyZag Bio Announces $80 Million Series AZag Bio, a Cambridge, Massachusetts-based biotech startup, announced an $80 million Series A financing round led by T1D Fund and Polaris Partners. Polaris Partners both led the round and founded and incubated the company. This substantial Series A funding will support the company's operations and growth in the competitive biotech sector.Venture Capital Access OnlineZag Bio™ Launches with $80 Million Financing to Advance Thymus-targeted Medicines for Autoimmune DiseasesZag Bio, Inc., a biotechnology company pioneering thymus-targeted medicines for autoimmune diseases, launched on October 28, 2025, with $80 million in Series A financing co-led by Polaris Partners and the T1D Fund, with participation from Mission BioCapital, AbbVie Ventures, Lightspeed Ventures, Sanofi Ventures, KdT Ventures, Regeneron Ventures, Boxer Capital, Pear VC, Codon Capital, Alexandria Venture Investments and Gaingels. The company appointed Jason F. Cole as Chief Executive Officer and is advancing its lead program ZAG-101, a tolerogenic therapy for Type 1 diabetes, toward clinical development expected in late 2026. The financing will also support discovery programs targeting a broad range of other autoimmune diseases using Zag Bio's proprietary thymus-targeting bifunctional antibody platform.GlobeNewswireZag Bio™ Launches with $80 Million Financing to AdvanceZag Bio, Inc., a biotechnology company pioneering thymus-targeted medicines for autoimmune diseases, launched with $80 million in Series A financing co-led by Polaris Partners and the T1D Fund, with participation from multiple venture capital firms. The company also appointed Jason F. Cole as Chief Executive Officer and is advancing its lead program ZAG-101, a tolerogenic therapy for Type 1 diabetes, toward clinical development with IND-enabling studies planned for late 2026.